Three SAMHSA overdose prevention grants close on the same day — Monday, July 27 — and together they put roughly $114 million on the table for organizations that move this week. The smallest of the three, Preventing Drug Overdoses: Community Prevention and Response (TI-26-019), offers $11.05 million across an anticipated 13 awards of up to $850,000 per year for three years, with no match required. The catch is not the paperwork. It is that SAMHSA has rewritten what its money can buy, and applications drafted from a 2024-era template will fund themselves straight into a rejection.

Three SAMHSA Overdose Prevention Grants Close July 27

The pileup is deliberate. On July 6, SAMHSA announced more than $281 million across 15 grant programs under the administration’s Great American Recovery Initiative, and stacked most of the overdose-facing deadlines onto the same Monday. That gave applicants roughly three weeks from posting to submission — a fraction of the 60-day windows SAMHSA ran in prior cycles.

Here is the July 27 slate, by the numbers:

• TI-26-019 — Preventing Drug Overdoses: Community Prevention and Response. $11.05 million total, an anticipated 13 awards, budgets capped at $850,000 per year across a three-year project. The purpose is community-wide prevention of overdose deaths by expanding access to FDA-approved opioid overdose reversal medications. Eligibility is broad: domestic public and private nonprofit entities, including faith-based organizations.
• TI-26-008 — Medication-Assisted Treatment – Prescription Drug and Opioid Addiction. The heavyweight: $68.2 million, an anticipated 91 awards around $750,000 each. Recipients must ensure access to methadone directly or through coordination, and ensure prescribers complete buprenorphine training.
• TI-26-006 — First Responders-Comprehensive Addiction and Recovery Act. $34.7 million to train first responders and community organizations to carry and administer opioid overdose reversal medications.

Two days behind them, TI-26-013 (Comprehensive Opioid Recovery Centers) closes July 29, per the SAMHSA grants dashboard. If your board cannot authorize a submission in seven days, that is the fallback door — not a reason to force a rushed application through the wrong one.

Which July 27 Door Fits Your Organization

Applying to the wrong NOFO wastes the only week you have. The fit logic is cleaner than the program names suggest.

Community nonprofits, coalitions, and faith-based organizations belong in TI-26-019. It is the only one of the three built for organizations whose core work is distribution, education, and response coordination rather than clinical treatment. If your organization can document local overdose mortality data and letters of commitment from health departments, law enforcement, and treatment providers, this is your lane. A grant discovery database can confirm whether parallel state or foundation dollars can cover what this NOFO will not.

Treatment providers with medical capacity should weigh TI-26-008 instead. The 91-award count makes it statistically the most winnable program SAMHSA has posted this year, but the methadone-access and buprenorphine-training requirements mean pure prevention shops need not apply. Organizations already delivering medication for opioid use disorder will find the compliance lift modest; everyone else should partner rather than stretch.

Fire departments, EMS agencies, and police-adjacent nonprofits map to TI-26-006, which funds training and naloxone carriage for the people most likely to reach an overdose first. Reporting by Filter notes these grants now emphasize “community anchor” organizations — with faith-based groups called out — since syringe service programs are no longer eligible applicants.

One application, or two?

Nothing bars an organization from applying to two doors where it is eligible for both, and the modified TI-26-019 notice explicitly contemplates current recipients returning with proposals for different populations or geographic areas. But each application needs its own need data, its own budget, and its own partner letters. With a week left, one strong application beats two thin ones — a rule any experienced grant writer will enforce before a funder does.

The Line Items SAMHSA Will and Won’t Fund Now

This is where 2026 applications die. Every notice in the July 6 batch states that the application and budget narrative must not support harm reduction — and SAMHSA has defined that term with a specificity that surprises returning applicants. The agency’s April 24, 2026 Dear Colleague letter draws the line item by item.

Fundable with SAMHSA dollars: purchase and distribution of opioid overdose reversal medications, including naloxone and nalmefene; medication lock boxes and disposal kits; overdose reversal education and training; and the bags or containers used to distribute reversal medications.

Not fundable with any HHS money, directly or through reimbursement: syringes or needles for illicit drug use, safer-smoking supplies, fentanyl test strips or any other drug-checking strips (xylazine and medetomidine included), overdose hotlines whose primary function is accompanying someone while they use, and sterile water, saline, or ascorbic acid used to facilitate use.

The practical consequence: a budget narrative that worked in 2023 — naloxone plus test strips plus supply distribution — now contains prohibited line items sitting next to allowable ones. Reviewers do not strike the bad lines and fund the rest. Scrub the budget, the narrative, and the logic model for any activity on the prohibited list, and reframe the program around reversal-medication access, training, and response coordination. Organizations that rely on the barred activities should route around federal funding entirely; our guide to nonprofit grants covers foundation and state channels that carry no such restrictions.

The Compliance Letters Most Applicants Forget

TI-26-019 carries two coordination requirements that trip up first-time federal applicants, and both have deadline-day implications. Under Executive Order 12372, applicants in participating states must notify their State Single Point of Contact. Separately, a Public Health System Impact Statement must be sent to the appropriate state and local health agencies by the application deadline — not after award. Neither is hard, but both require sending documents to state offices before July 27, which means starting them now, not during final upload.

Add the standing mechanics of any federal grant: an active SAM.gov registration (renewals can take days if validation snags), a Grants.gov workspace, and the SF-424 package with a budget on SF-424A. SAMHSA also updated TI-26-019 mid-cycle — clarifying language on pages 9 and 23 about new and current recipients — so download the current NOFO PDF rather than drafting from a version saved earlier in July. Continuation awards are contingent on progress, timely data submission, and alignment with stated agency priorities, so the sustainability section should read as an operations plan, not a wish.

Seven Days: A Triage Plan

Day one belongs to the go/no-go call: eligibility confirmed against the NOFO, mortality data in hand, and a partner list you can actually get letters from by Friday. Days two through four are the narrative and budget — written to the allowability ledger above — while a colleague chases the SPOC notification and health-agency letters in parallel. Days five and six are internal review and the Grants.gov upload dry run. Submit on day six. Grants.gov rejects late submissions automatically, and a validation error at 11:50 p.m. on July 27 is not an appealable event.

If the honest answer on day one is no-go, spend the same week productively: TI-26-013 buys you two extra days if recovery-center services fit your model, and SAMHSA’s FY2026 forecast dashboard lists the programs expected to post later this cycle. Building a submission-ready file against a forecast entry — need data, partners, budget skeleton — is how this month’s losers become next cycle’s first movers. The funder directory can round out that file with the state agencies and foundations funding overdose work on calendars SAMHSA does not control.

Frequently Asked Questions

Who is eligible for the TI-26-019 overdose prevention grant?

Q: Can any nonprofit apply?
A: Eligibility covers domestic public and private nonprofit entities, including faith-based organizations — one of the broadest applicant pools in the July 27 cluster. That said, competitive applications document elevated local overdose mortality, name committed partners across health departments, emergency services, and treatment providers, and show organizational capacity to distribute reversal medications at community scale. Broad eligibility gets you in the door; local data wins the score.

How much money can we request?

Q: What is the award size for these SAMHSA overdose prevention grants?
A: TI-26-019 budgets cannot exceed $850,000 in total costs — direct and indirect — in any year of the three-year project, and SAMHSA anticipates 13 awards from $11.05 million. TI-26-008 anticipates roughly 91 awards near $750,000 each from $68.2 million. Continuation funding each year depends on progress, timely reporting, and available appropriations, so treat year one as an audition rather than an entitlement.

Can current SAMHSA grantees apply again?

Q: We already hold an overdose prevention award. Are we locked out?
A: No. SAMHSA modified the TI-26-019 notice in July specifically to clarify that new and current recipients may submit applications focused on different populations or geographic areas. A current grantee serving one county can propose an adjacent county or a distinct population. What you cannot do is submit a duplicate of your funded project — the differentiation must be real and documented in the need section.

Is naloxone distribution still fundable?

Q: With harm reduction barred, can we still buy naloxone?
A: Yes — emphatically. SAMHSA’s April 2026 guidance classifies opioid overdose reversal medications, including naloxone and nalmefene, as life-saving overdose prevention services, alongside lock boxes, disposal kits, training, and distribution containers. What moved to the prohibited list are syringes, safer-smoking supplies, drug-checking strips, and use-accompaniment hotlines. Budget narratives should use the agency’s own framing: reversal-medication access, not harm reduction.

Bottom Line

The July 27 cluster is the largest simultaneous release of SAMHSA overdose prevention grants this fiscal year, and it rewards two things: picking the door that matches your organization, and drafting to the 2026 allowability rules rather than a pre-2025 template. The $114 million is real, the windows are short by design, and the programs’ priorities are stated plainly in the notices for anyone who reads them.

The specific move this week: run the day-one go/no-go against TI-26-019’s eligibility and data requirements, scrub every budget line against the April Dear Colleague letter, and get the SPOC and health-agency letters moving before the narrative is finished. If drafting capacity is the bottleneck between your organization and a compliant July 27 submission, OpenGrants’ grant writing services can carry the application while your team secures the partner letters — this cycle, not next year’s.